Format

Send to

Choose Destination
World J Urol. 2010 Aug;28(4):487-92. doi: 10.1007/s00345-009-0477-y. Epub 2009 Oct 16.

Arsenic exposure predicts bladder cancer survival in a US population.

Author information

1
Section of Biostatistics and Epidemiology, Department of Community and Family Medicine, Norris Cotton Cancer Center, Dartmouth Medical School, 7927 Rubin 860 One Medical Center Drive, Lebanon, NH 03756, USA.

Abstract

PURPOSE:

Chronic arsenic exposure at levels found in US drinking water has been associated with bladder cancer. While arsenic is a known carcinogen, recent studies suggest that it is useful as a therapeutic agent for leukemia. This study examined the relationship between arsenic exposure and bladder cancer mortality.

METHODS:

We studied 832 cases of bladder cancer diagnosed in New Hampshire from a population-based case-control study. Individual exposure to arsenic was determined in home drinking water using ICP-MS and in toenail samples by instrumental neutron activation analysis.

RESULTS:

Among the high arsenic exposure group, found using toenail arsenic level or arsenic consumption, cases experienced a de-escalated survival hazard ratio (HR) [high (> or =75 percent) versus low (<25th percentile) toenail arsenic overall survival HR 0.5 (95% CI 0.4-0.8)], controlled for tumor stage, grade, gender, age and treatment regimen. This association was found largely among invasive tumors, in smokers and was not modified by TP53 status. Bladder cancer cause-specific survival showed a similar trend, but did not reach statistical significance [HR 0.5 (95% CI 0.3-1.1)].

CONCLUSIONS:

Arsenic exposure may be related to the survival of patients with bladder cancer.

PMID:
19834714
PMCID:
PMC3296964
DOI:
10.1007/s00345-009-0477-y
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Springer Icon for PubMed Central
Loading ...
Support Center